Johnson & Johnson and CSIR-IMTECH to work along for exploring new TB treatments – ZMR Blog
Trending News & Updates

Johnson & Johnson and CSIR-IMTECH to work along for exploring new TB treatments

A development-based alliance was announced among Johnson & Johnson Pvt. Ltd. and IMTECH the Institute of Microbial Technology, which is the division of the (CSIR) Council of Scientific and Industrial Research. The move came in with an objective to explore the possibilities of Indian science and boost the speed of discovering new innovative treatment methods for tuberculosis.
As per the inked MoU, researchers of Johnson & Johnson’s health team will function directly with CSIR-IMTECH’s scientists at Chandigarh, India. Both the teams will collaboratively work to explore more effective, fully oral treatments procedure to handle the case of multidrug-resistant TB (MDR-TB) and also to develop new molecular compounds for the treatment of tuberculosis patients.csr

“We have integrated with India with our fortitude to eliminate TB totally and put it back in the history. As we have accomplished some immense and appreciable advancement in present years with the consent of innovative TB medicines, there is a lot more to be achieved. By collating a few of India’s talented brains along with our scientists, the possibilities to accomplish key study breakthrough will be spurred, which can direct towards pioneering fresh treatment methods for the patients suffering from TB, not only in India but also across the globe,” said Paul Stoffels, M.D., Chief Scientific Officer of Johnson & Johnson. He joined Dr. Harsh Vardhan, Minister for Science and Technology, to declare the Memorandum of Understanding.

“The innovative research course will take advantage of CSIR-IMTECH’s superlative capabilities in microbial research & technology, and verified investigation, as well as the advance potential of Johnson & Johnson’s Janssen Pharmaceutical Companies, will fortify the combined perspective of our research endeavor,” he added.


Dr. Anil Koul, Director of CSIR-IMTECH, said, “The disease dominates as a considerable challenge in the country, taking under its influence and killing almost half million patients in 2015.”

He also said the alliance announced with J&J has capabilities to increase the speed of work in support of India’s National Strategic Plan and our accelerated plan of action to vanish off tuberculosis by 2025 and mainly save lives.

Today’s declaration comes on the grounds of 20 Years of research and development on tuberculosis by J&J, resulting to the sanction of bedaquiline, which is the first newly developed TB drug in the last 50 Years. It also adds to present collaboration at State and Central levels in India to escalate the awareness, care, diagnoses and widen accessibility to bedaquiline.

Leave A Reply

Your email address will not be published.